NASDAQ · XCURHealthcarePharmaceuticals

Exicure financials

$1.14−7.69%
Close Sep 29, 2026 · split-adjusted

Revenue

Net income

Income statement & cash flow

Fiscal yearFY25
Dec 31
FY24
Dec 31
FY23
Dec 31
FY22
Dec 31
FY21
Dec 31
FY20
Dec 31
FY19
Dec 31
Revenue$0.00$500.0K$0.00$28.8M-$483.0K$16.6M$1.3M
Gross profit$0.00$500.0K$0.00$28.8M-$483.0K$16.6M$1.3M
Gross margin—100.0%—100.0%100.0%100.0%100.0%
Operating income-$4.1M-$12.2M-$14.1M-$1.8M-$62.5M-$25.4M-$26.6M
Net income-$4.9M-$9.7M-$16.9M-$2.6M-$64.1M-$24.7M-$26.3M
Net margin—−1940.2%—−9.0%13271.6%−148.5%−2029.6%
Diluted EPS$-0.79$-4.75$-10.55$-2.80$-108.50$-42.00$-69.00
EBITDA-$9.9M-$4.9M-$12.5M-$668.0K-$60.8M-$24.0M-$26.2M
Operating cash flow-$8.6M-$2.9M-$10.4M-$35.7M-$34.8M-$39.3M$1.3M
Free cash flow-$8.6M-$2.9M-$10.4M-$35.7M-$35.8M-$42.4M$235.0K
Diluted shares6.3M2.0M1.6M0.9M0.6M0.6M0.4M

Balance sheet

Period endDec 31Dec 31Dec 31Dec 31Dec 31Dec 31
Cash & equivalents$3.7M$12.5M$816.0K$8.6M$34.6M$33.3M
Short-term investments$0.00$0.00$0.00$0.00$4.5M$48.8M
Total debt$0.00$0.00$0.00$0.00$6.9M$16.6M
Total assets$14.0M$15.1M$11.6M$23.3M$64.9M$100.4M
Total liabilities$10.1M$8.3M$8.5M$8.4M$53.6M$38.9M
Shareholders' equity$3.9M$6.8M$3.0M$14.9M$11.2M$61.5M

From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology